NCT02268864 - A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

April 30, 2016

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Simeprevir

Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.

DRUG

Daclatasvir

Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.

Trial Locations (23)

Antwerp

Brussels

Ghent

Créteil

Lyon

Montpellier

Nice

Paris

Vandœuvre-lès-Nancy

Frankfurt

Hamburg

Hanover

Kiel

Tübingen

Würzburg

Budapest

Debrecen

Badalona

Barcelona

Santander

Valencia

Birmingham

London